Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsVentura County Avandia Prior Auth | OpenPayer
    Ask Trek AI about this page
    ModifiedVentura County Health Care PlanPolicy N/A

    Avandia (rosiglitazone) Prior Authorization Criteria

    Customize your policy alerts

    Sign up for all venturacountyhealthcareplan policy alerts

    Know when venturacountyhealthcareplan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and coverage of Avandia (rosiglitazone) for adults with type 2 diabetes mellitus. It specifies required prior therapies, clinical contraindications, precautions, and dosing-related safety considerations.

    Policy Summary
    PayerVentura County Health Care Plan
    PolicyAvandia (rosiglitazone) Prior Authorization Criteria
    Policy CodePolicy N/A
    Change TypeModified
    Effective DateJanuary 28, 2014
    Last ReviewFeb 18, 2025
    Next Review DateN/A
    Key ActionSubmit prior authorization documenting adult type 2 diabetes, adjunctive use with diet and exercise, and failure or intolerance of required prior therapies.
    SourceLink
    POLICY UPDATE CHANGES

    The authorization criteria were modified to cover treatment of type 2 diabetes rather than type 1 diabetes.

    The Medication Guide and Prescribing and Access Restrictions sections were removed.

    The precautions section was updated in the 2021 revision.

    Type 2 diabetesCovered disease indication
    5 classesRequired prior therapies before Avandia coverage
    NYHA III-IV CHFExplicit contraindication

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    ALT >2.5x ULNBaseline threshold preventing treatment initiation
    4-8 mg dailyAdult dosing range
    U.S. discontinuedProduct availability

    Avandia Coverage Criteria

    Initial Therapy Coverage Criteria

    Covered when all of the following are met:

    Covered indication and treatment setting: The patient is an adult with type 2 diabetes mellitus and will use Avandia (rosiglitazone) as an adjunct to diet and exercise.

    Therapy may be used as monotherapy or in combination with metformin or a sulfonylurea, particularly when other therapies are ineffective or associated with intolerable side effects.

    Required prior therapy sequence

    • Prior medication classes: The patient has tried metformin, a glucagon-like peptide-1 (GLP-1) agent, a dipeptidyl-peptidase-4 (DPP-4) agent, an alpha-glucosidase inhibitor (AGI), and insulin when the patient is normal weight.5 required classes

    Safety and Contraindication Criteria

    All safety requirements must be satisfied before initiation:

    Hepatic safety: The patient does not have active liver disease and baseline ALT is not greater than 2.5 times the upper limit of normal.ALT ≤ 2.5 times ULN at baseline

    Discontinue therapy if ALT exceeds 3 times ULN on verified follow-up or if jaundice occurs.

    Cardiac safety: The patient does not have NYHA class III-IV congestive heart failure and does not have symptomatic congestive heart failure.

    Thiazolidinediones may cause or exacerbate congestive heart failure; monitor for fluid retention, dyspnea, edema, and rapid excessive weight gain after initiation or dose increases.

    Concomitant therapy safety: Rosiglitazone is not used concomitantly with insulin.

    Concomitant use increases the risk of edema, congestive heart failure, and myocardial ischemic events.

    Do not initiate rosiglitazone in patients with active liver disease or when baseline ALT is greater than 2.5 times the upper limit of normal.

    Rosiglitazone is contraindicated in NYHA class III-IV congestive heart failure and is not recommended in patients with symptomatic congestive heart failure. Thiazolidinediones may cause or exacerbate heart failure; monitor closely after treatment initiation or dose increases for rapid excessive weight gain, dyspnea, or edema.

    Do not use rosiglitazone concomitantly with insulin because of the increased risk of edema, congestive heart failure, and myocardial ischemic events.

    Rosiglitazone is not recommended for type 1 diabetes (insulin-dependent diabetes) because its mechanism of action requires the presence of insulin.

    Safety Thresholds and Dose Management

    Baseline ALT
    Treatment initiationDo not initiate therapy in patients with active liver disease or ALT greater than 2.5 times the upper limit of normal.
    Baseline hepatic assessmentAssess hepatic status and obtain baseline ALT before starting therapy.
    Baseline limitALT must be at or below 2.5 times the upper limit of normal at baseline.
    ALT Discontinuation Threshold
    Discontinue therapyDiscontinue if ALT is greater than 3 times the upper limit of normal, verified by a follow-up level, or if jaundice occurs.
    Follow-up verificationAn ALT greater than 3 times the upper limit of normal must be verified by a follow-up level before discontinuation based on the laboratory threshold.

    Authorization and Documentation Requirements

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for Avandia (rosiglitazone) or other thiazolidinediones. The request must document the covered indication of adult type 2 diabetes mellitus treated as an adjunct to diet and exercise.

    • Document whether therapy is being used as monotherapy or in combination with metformin or a sulfonylurea.
    • Explain why other therapies were ineffective or caused intolerable side effects.
    Step Therapy

    Required Prerequisite Therapies

    Before Avandia or another thiazolidinedione is covered, document trials of the required first-, second-, and third-line therapies, unless contraindicated or not applicable.

    • Metformin
    • Glucagon-like peptide-1 (GLP-1) therapy
    • Dipeptidyl-peptidase-4 (DPP-4) therapy

    Medication Background

    Rosiglitazone is a thiazolidinedione antidiabetic agent that improves target-cell response to insulin. It is used with diet and exercise in adults with type 2 diabetes.

    Key Clinical Terms

    Rosiglitazone
    Drug classRosiglitazone is a thiazolidinedione antidiabetic agent.
    Glucose-lowering effectLowers blood glucose by improving target-cell response to insulin without increasing pancreatic insulin secretion.
    MechanismActs as an agonist for peroxisome proliferator-activated receptor-gamma (PPARgamma), influencing gene products involved in glucose and lipid metabolism.
    Congestive Heart Failure Risk
    Fluid retentionThiazolidinediones can cause fluid retention by increasing sodium reabsorption, which may cause or exacerbate congestive heart failure.
    Boxed-warning symptomsAfter treatment initiation or dose increases, monitor closely for excessive rapid weight gain, dyspnea, and edema.

    Initial Avandia Authorization

    Initial Avandia Authorization

    Initial Avandia therapy is covered only when all authorization and prerequisite therapy requirements are met:

    Indication: The patient is an adult with type 2 diabetes mellitus and will use Avandia as an adjunct to diet and exercise.

    Avandia may be used as monotherapy or in combination with metformin or a sulfonylurea when appropriate.

    Prior treatment failure or intolerance

    • Required prerequisite therapies: The patient has tried metformin, a glucagon-like peptide-1 (GLP-1) agent, a dipeptidyl-peptidase-4 (DPP-4) agent, an alpha-glucosidase inhibitor (AGI), and insulin when the patient is normal weight.5 required medication classes

    Required Treatment Sequence

    StepRequired prerequisite therapyRequirement before Avandia or another thiazolidinedione
    1Metformin; glucagon-like peptide-1 (GLP-1) agent; dipeptidyl-peptidase-4 (DPP-4) agent; alpha-glucosidase inhibitor (AGI); and insulin in normal-weight patientsAll listed therapies must be tried first. Thiazolidinediones are considered only when prior therapies are ineffective or associated with intolerable side effects.
    Policy Summary
    PayerVentura County Health Care Plan
    PolicyAvandia (rosiglitazone) Prior Authorization Criteria
    Policy CodePolicy N/A
    Change TypeModified
    Effective DateJanuary 28, 2014
    Last ReviewFeb 18, 2025
    Next Review DateN/A
    Key ActionSubmit prior authorization documenting adult type 2 diabetes, adjunctive use with diet and exercise, and failure or intolerance of required prior therapies.
    SourceLink
    On This Page
    Avandia Coverage CriteriaSafety Thresholds and Dose ManagementAuthorization and Documentation RequirementsMedication BackgroundKey Clinical TermsInitial Avandia AuthorizationRequired Treatment Sequence
    Clinical monitoringMonitor for signs of liver injury, including jaundice, during treatment.
    Dose Reassessment
    Initial doseInitiate at 4 mg daily, given as a single daily dose or in divided doses twice daily.
    ReassessmentReassess response after 8–12 weeks of treatment.
    Dose increaseIf response is inadequate after 8–12 weeks, increase the dosage to 8 mg daily, given as a single daily dose or in divided doses twice daily.
  1. Alpha-glucosidase inhibitor (AGI)
  2. Insulin in normal-weight patients
  3. Documentation Required

    Indication and Treatment History

    Document that the patient is an adult with type 2 (noninsulin-dependent) diabetes mellitus and that Avandia or the thiazolidinedione will be used as an adjunct to diet and exercise. Include the treatment history and rationale, including prior ineffective therapies or intolerable adverse effects; use may be as monotherapy or with metformin or a sulfonylurea.

    • The policy follows the AACE 2013 Comprehensive Diabetes Management Algorithm, under which thiazolidinediones are reserved for cases in which other first-, second-, and third-line therapies are ineffective or not tolerated.
    Documentation Required

    Baseline Liver Assessment

    Assess and document hepatic status and baseline ALT before initiation. Do not initiate therapy in patients with active liver disease, symptoms of active liver disease, or ALT greater than 2.5 times the upper limit of normal.

    • Discontinue therapy if verified follow-up ALT exceeds 3 times the upper limit of normal or jaundice develops.
    • Document baseline liver assessment and transaminase results in the authorization request.
    Denial Risk

    Heart Failure Risk Assessment

    Assess and document any history of heart failure, current symptoms, and NYHA functional class before treatment. Thiazolidinediones are contraindicated in NYHA Class III-IV congestive heart failure and are not recommended in symptomatic heart failure.

    • After initiation or dose increases, monitor closely for excessive or rapid weight gain, dyspnea, and edema.
    • If heart-failure signs or symptoms develop, manage according to current standards and consider dose reduction or discontinuation.
    Denial Risk

    Common Denial Conditions

    Coverage may be denied when the request is for a noncovered indication, required prerequisite therapies are not documented, or safety restrictions are not met.

    • Type 1 diabetes is not a recommended indication.
    • Deny or do not initiate when active liver disease or baseline ALT >2.5 times the upper limit of normal is present.
    • Deny when NYHA Class III-IV heart failure is present; symptomatic heart failure is not recommended for treatment.
    • Deny when required trials of metformin, GLP-1, DPP-4, AGI, and insulin in normal-weight patients have not been completed or adequately explained.
    Denial Risk

    Concomitant Insulin Risk

    Do not use Avandia or another thiazolidinedione concomitantly with insulin. The combination increases the risk of edema, congestive heart failure, and myocardial ischemic events.

    • Review the medication list and address concurrent insulin before approval or initiation.
    • Monitor for fluid retention and heart-failure symptoms if relevant treatment changes occur.
    Denial Risk

    Type 1 Diabetes Exclusion

    Do not use rosiglitazone for type 1 (insulin-dependent) diabetes. Its mechanism requires the presence of endogenous insulin, so it is not recommended when insulin dependence is present.

    • Confirm and document type 2, noninsulin-dependent diabetes before authorization.
    Avoidance criteriaRosiglitazone is contraindicated in NYHA class III–IV congestive heart failure and is not recommended in symptomatic congestive heart failure.
    Response to symptomsIf heart failure signs or symptoms develop, manage according to current care standards and consider discontinuation or dose reduction.